{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:51:55Z","timestamp":1771512715719,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen"},{"name":"Abbott Labs"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stiefel"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Anacor"},{"name":"UpToDate"},{"name":"Xlibris"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eli Lilly"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.det.2017.11.009","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T14:04:48Z","timestamp":1513865088000},"page":"135-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Review of the Current Modalities for the Treatment of Papulopustular Rosacea"],"prefix":"10.1016","volume":"36","author":[{"given":"Sean P.","family":"McGregor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Alinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Moradi","family":"Tuchayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Alan","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2133.2012.11037.x","article-title":"A\u00a0study on the epidemiology of rosacea in the U.K","volume":"167","author":"Spoendlin","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6 Suppl 1","key":"10.1016\/j.det.2017.11.009_bib3","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2013.04.043","article-title":"Rosacea: current state of epidemiology","volume":"69","author":"Tan","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"14","key":"10.1016\/j.det.2017.11.009_bib4","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1517\/14656566.2014.945423","article-title":"Management of cutaneous rosacea: emphasis on new medical therapies","volume":"15","author":"Del Rosso","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.det.2017.11.009_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib6","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Ivermectin phase III study group. Superiority of ivermectin 1% cream over metronidazole 0\u00b775% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5 Suppl","key":"10.1016\/j.det.2017.11.009_bib8","first-page":"7","article-title":"An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads)","volume":"86","author":"Webster","year":"2010","journal-title":"Cutis"},{"issue":"5 Suppl","key":"10.1016\/j.det.2017.11.009_bib9","first-page":"16","article-title":"Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial","volume":"86","author":"Del Rosso","year":"2010","journal-title":"Cutis"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib10","first-page":"573","article-title":"Comparison of anti-inflammatory dose: doxycycline versus doxycycline 100 mg in the treatment of rosacea","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib12","first-page":"641","article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler","year":"2007","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies","volume":"48","author":"Thiboutot","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib14","first-page":"306","article-title":"Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study","volume":"92","author":"Draelos","year":"2013","journal-title":"Cutis"},{"issue":"7","key":"10.1016\/j.det.2017.11.009_bib15","first-page":"639","article-title":"A\u00a0multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy","volume":"8","author":"Thiboutot","year":"2009","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib16","first-page":"541","article-title":"Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea","volume":"7","author":"Thiboutot","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib17","first-page":"292","article-title":"Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea","volume":"12","author":"Jackson","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.det.2017.11.009_bib18","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","article-title":"A\u00a0comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial","volume":"139","author":"Elewski","year":"2003","journal-title":"Arch Dermatol"},{"issue":"6 Pt 1","key":"10.1016\/j.det.2017.11.009_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0190-9622(99)70085-X","article-title":"A\u00a0comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea","volume":"40","author":"Maddin","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib20","first-page":"607","article-title":"Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea","volume":"9","author":"Del Rosso","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2005.04.069","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea","volume":"53","author":"Sanchez","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archderm.134.6.679","article-title":"Topical metronidazole maintains remissions of rosacea","volume":"134","author":"Dahl","year":"1998","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.009_bib23","first-page":"73","article-title":"The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea","volume":"79","author":"Wolf","year":"2007","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","article-title":"Topical metronidazole therapy for rosacea","volume":"123","author":"Bleicher","year":"1987","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0190-9622(98)70337-8","article-title":"The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial","volume":"39","author":"Jorizzo","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1067\/mjd.2001.116219","article-title":"Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea","volume":"45","author":"Dahl","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib27","first-page":"357","article-title":"Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea","volume":"75","author":"Torok","year":"2005","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-4632.2004.02130.x","article-title":"Adapalene vs. metronidazole gel for the treatment of rosacea","volume":"44","author":"Altinyazar","year":"2005","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2230.2009.03427.x","article-title":"A\u00a0comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial","volume":"35","author":"Koca","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.det.2017.11.009_bib30","first-page":"1410","article-title":"Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial","volume":"11","author":"Freeman","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib31","first-page":"333","article-title":"A\u00a0randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks","volume":"11","author":"Chang","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-4632.2004.02283.x","article-title":"Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide\/clindamycin topical gel in the treatment of patients with moderate to severe rosacea","volume":"43","author":"Breneman","year":"2004","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archderm.1994.01690030051008","article-title":"A\u00a0comparison of the\u00a0efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea","volume":"130","author":"Ertl","year":"1994","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.009_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(03)02157-1","article-title":"Tacrolimus effect on rosacea","volume":"50","author":"Bamford","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2017.11.009_bib35","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1346-8138.2011.01223.x","article-title":"Pimecrolimus 1% cream for the treatment of rosacea","volume":"38","author":"Kim","year":"2011","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1468-3083.2008.02589.x","article-title":"A\u00a0randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea","volume":"22","author":"Karabulut","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1365-2133.2006.07669.x","article-title":"Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial","volume":"156","author":"Weissenbacher","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib38","first-page":"664","article-title":"Efficacy and tolerability of low molecular weight hyaluronic acid sodium salt 0.2% cream in rosacea","volume":"12","author":"Schlesinger","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib39","first-page":"459","article-title":"124 (0.125%) lotion for improving the signs and symptoms of rosacea","volume":"8","author":"Ortiz","year":"2009","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-4632.2011.05353.x","article-title":"Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea","volume":"51","author":"Bamford","year":"2012","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.009_bib41","first-page":"18","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies","volume":"93","author":"Del Rosso","year":"2014","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib42","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaad.2014.08.027","article-title":"Rosacea: part II. Topical and systemic therapies in the treatment of rosacea","volume":"72","author":"Two","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2017.11.009_bib43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1211\/jpp.59.8.0010","article-title":"Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system","volume":"59","author":"Narayanan","year":"2007","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"6","key":"10.1016\/j.det.2017.11.009_bib44","first-page":"277","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents","volume":"92","author":"Del Rosso","year":"2013","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib45","first-page":"134","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea","volume":"93","author":"Del Rosso","year":"2014","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib46","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2013.05.019","article-title":"Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel","volume":"69","author":"Coda","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2 Suppl","key":"10.1016\/j.det.2017.11.009_bib47","first-page":"7","article-title":"The rationale for advancing the formulation of azelaic acid vehicles","volume":"77","author":"Draelos","year":"2006","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib48","first-page":"257","article-title":"Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel","volume":"74","author":"Draelos","year":"2004","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib49","first-page":"317","article-title":"Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%","volume":"79","author":"Col\u00f3n","year":"2007","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.det.2017.11.009_bib50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1472-8206.2009.00684.x","article-title":"Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway","volume":"23","author":"Ci","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib51","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1365-2133.2012.11114.x","article-title":"Positive correlation between serum immunoreactivity to Demodex-associated Bacillus proteins and erythematotelangiectatic rosacea","volume":"167","author":"O'Reilly","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2017.11.009_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-4632.2004.01958.x","article-title":"Therapeutic potential of azithromycin in rosacea","volume":"43","author":"Bakar","year":"2004","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.009_bib53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-4632.2008.03445.x","article-title":"Comparison of efficacy azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial","volume":"47","author":"Akhyani","year":"2008","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1468-3083.2000.00086-2.x","article-title":"A\u00a0novel treatment for acne vulgaris and rosacea","volume":"14","author":"Elewski","year":"2000","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2017.11.009_bib55","first-page":"585","article-title":"The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life","volume":"4","author":"Fleischer","year":"2005","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.009_bib56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaad.2015.02.1121","article-title":"Assessment of rosacea severity: a review of evaluation methods used in clinical trials","volume":"73","author":"Hopkinson","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.11.009_bib57","article-title":"Interventions for rosacea","volume":"4","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863517301675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863517301675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:42:36Z","timestamp":1668688956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863517301675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0733863517301675"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2017.11.009","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of the Current Modalities for the Treatment of Papulopustular Rosacea","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2017.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}